Abstract: The present application relates to methods of treating IgE-mediated disorders comprising the administration of highly concentrated anti-IgE antibody formulations with reduced viscosity that are stable, relatively isotonic and are of low turbidity. The formulations are particularly suitable for subcutaneous administration.
Abstract: This invention relates to binding members, especially antibody molecules, for IgE. The binding members are useful for, inter alia, treatment of disorders mediated by IgE including allergies and asthma.
Type:
Application
Filed:
February 15, 2008
Publication date:
June 17, 2010
Applicant:
AstraZeneca AB
Inventors:
Duncan Cochrane, Suzanne Cohen, Louise Claire Dobson, Fredick Per-Olof Eriksson, David Phillip Monk, Karin Von-Wachenfeldt
Abstract: The present invention provides methods for preventing or treating a medical disorder in a subject comprising administering to the subject an effective amount of a stable pharmaceutical formulation comprising an antibody or antigen-binding fragment thereof.
Abstract: This invention provides for a method for inhibiting new tissue growth in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit new tissue growth in the subject's blood vessels. The invention also provides for method for inhibiting neointimal formation in blood vessels in a subject, wherein the subject experienced blood vessel injury, which comprises administering to the subject a pharmaceutically effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) so as to inhibit neointimal formation in the subject's blood vessels.
Type:
Grant
Filed:
August 20, 2007
Date of Patent:
June 8, 2010
Assignees:
The Trustees of Columbia University in the City of New York, The Cleveland Clinic Foundation
Inventors:
David M. Stern, Ann Marie Schmidt, Steven Marso, Eric Topol, A. Michael Lincoff
Abstract: This invention relates to compositions and methods for the use of anti-autoimmune reagents that specifically bind to anti-desmoglein antibodies, which are responsible for both pemphigus vulgaris and pemphigus foliaceus. In addition, the invention relates to methods and compositions for inhibiting the expression or function of a variable region of an anti-desmoglein (anti-Dsg) pathogenic autoantibody.
Type:
Application
Filed:
January 25, 2008
Publication date:
June 3, 2010
Inventors:
Aimee S. Payne, John R. Stanley, Donald L. Siegel
Abstract: The present invention provides novel antibodies that specifically bind to an ORP150 polypeptide expressed of the cell surface of plasmacytoma, multiple myeloma, colorectal cancer cells, gastric cancer cells, or esophageal cancer cells. These antibodies can be used in a variety of diagnostic and therapeutic methods.
Type:
Application
Filed:
November 17, 2009
Publication date:
June 3, 2010
Inventors:
Chiu-Chen Huang, Shih-Yao Lin, Leewen Lin
Abstract: Disclosed herein are vaccine compositions comprising live attenuated virus with anti-antibody to improve efficacy. Specifically exemplified herein is a composition comprising live attenuated cold adapted influenza virus and an enhancing amount of IgG anti-IgA antibody to temporarily inactivate IgA defenses. Also disclosed herein are methods of immunizing a subject to protect against influenza comprising administering compositions taught herein.
Type:
Application
Filed:
March 19, 2008
Publication date:
April 29, 2010
Inventors:
Parker A. Small, JR., Bradley S. Bender
Abstract: The present invention relates to a method for diagnosis of a disease selected from the group of diabetes, vasculitis, collagenosis, an inflammatory rheumatic disease and arteriosclerosis wherein, presence or absence of an anti-AT1-receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease. The invention further relates to the use of an inhibitor of an anti-AT1-receptor antibody or an inhibitor of an AT1-receptor for the production of a medicament as well as plasmapheresis of blood for the removal of anti-AT1-receptor antibodies.
Abstract: The invention provides the use of intravenous immunoglobulin (IVIg) in the preparation of a medicament for the treatment and/or prophylaxis of mycobacterial infection.
Type:
Grant
Filed:
March 8, 2006
Date of Patent:
March 30, 2010
Assignee:
Medical Research Council
Inventors:
Stephen Jolles, Ricardo Tascon, Douglas Lowrie, Vangelis Stavropoulos
Abstract: The present invention relates to an antibody that recognizes a first antibody, the antibody specifically recognizing one of a free first antibody and an antigen-binding first antibody. More specifically, the above antibody is a domino antibody that specifically recognizes and binds to an antigen-binding first antibody, or an antibody-unlocking antibody that specifically recognizes and binds to a free first antibody.
Abstract: Novel anti-idiotype monoclonal antibodies are described which are capable of specifically reacting with the idiotype of human anti-gp120 antibodies, of inhibiting the binding between the gp120 antigen and human anti-gp120 antibodies, and of evoking a neutralising anti-gp120 immune response in an animal host to which they are administered. The anti-idiotype antibodies of the invention can be identified based on the amino acid sequences of the variable portions of their light and heavy chains. In addition, a method for obtaining a panel of anti-idiotype monoclonal antibodies, expression vectors and transformed host cells usable in a recombinant DNA procedure in order to generate the aforesaid anti-idiotype monoclonal antibodies, as well as the therapeutic, prophylactic and diagnostic use of such antibodies are disclosed.
Abstract: The present invention relates to a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable construct. The targetable construct comprises a carrier portion which comprises or bears at least one epitope recognizable by at least one arm of said bi-specific antibody or antibody fragment. The targetable construct further comprises one or more therapeutic or diagnostic agents or enzymes. The invention provides constructs and methods for producing the bi-specific antibodies or antibody fragments, as well as methods for using them.
Type:
Application
Filed:
May 29, 2009
Publication date:
January 14, 2010
Applicant:
IMMUNOMEDICS, INC.
Inventors:
David M. Goldenberg, Hans J. Hansen, William J. McBride
Abstract: The present invention relates to proteins which specifically bind to IgA1 and which have been modified to comprise either O- or N-linked glycans. The invention encompasses methods for decreasing IgA1, preferably abnormally glycosylated IgA1, in an individual by administering to the individual a glycan-modified IgA1 binding protein of the invention. The invention also encompasses a method for the treatment of a disease characterized by IgA1 deposition wherein a glycan-modified IgA1 binding protein is administered to an individual in need thereof.
Abstract: The invention relates to the treatment of autoimmune diseases and disorders, in particular myasthenia gravis, by administration of effector-function-deficient antibodies, wherein said effector-function-deficient antibodies are capable of competing with one or more of the auto-antibodies involved in mediating the antibody-mediated auto-immune disease or disorder for binding to a target auto-antigen.
Type:
Application
Filed:
December 15, 2006
Publication date:
December 24, 2009
Applicant:
GENMAB A/S
Inventors:
Mario Losen, Pilar Martinez-Martinez, Marc H. De Baets, Yvo Graus, Janine Schuurman, Paul Parren
Abstract: The present invention relates generally to neural development and neurological disorders. The invention specifically concerns identification of novel modulators of the myelin-associated inhibitory system and various uses of the modulators so identified.
Type:
Application
Filed:
May 13, 2009
Publication date:
November 19, 2009
Inventors:
Jasvinder Atwal, Marc Tessier-Lavigne, Yan Wu
Abstract: The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid ? protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes.
Type:
Application
Filed:
June 17, 2009
Publication date:
November 19, 2009
Inventors:
William L. Klein, Grant A. Krafft, Mary P. Lambert, Kirsten L. Viola, Brett A. Chromy, Lei Chang
Abstract: The present invention relates to the use of dihydropteridinones of formula 1 wherein the groups X, R1, R2, R3, R4, R5, R6 and R7 have the meanings given in the claims and specification, for the preparation of a medicament for the treatment of respiratory diseases.
Type:
Application
Filed:
March 13, 2009
Publication date:
November 12, 2009
Applicant:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Inventors:
Udo Maier, Frank Kalkbrenner, Frank Buettner, Steffen Breitfelder, Matthias Grauert, Matthias Hoffmann
Abstract: Provided are anti-idiotypic antibodies specific for a CDR of an anti-MMP-14 antibody for use as reagents in novel assays for anti-MMP-14 antibodies, pharmaceutical compositions and vaccines.
Type:
Application
Filed:
April 24, 2009
Publication date:
November 5, 2009
Applicant:
Dyax Corp.
Inventors:
Arumugam Muruganandam, Christopher Tenhoor, Laetitia Devy
Abstract: A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising an anti-IgE antibody for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.
Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A.
Type:
Application
Filed:
August 23, 2007
Publication date:
October 22, 2009
Inventors:
Jean-Guy Gilles, Marc G. Jacquemin, Jean-Marie Saint-Remy, Christian Behrens
Abstract: The present invention is related to a pharmaceutical composition for modulating angiogenesis comprising a therapeutically effective amount of an angiogenesis modulating compound and a pharmaceutically acceptable excipient, wherein said modulating compound is a recombinant of caveolin-1, a nucleic acid encoding the partial or total amino acid sequence of caveolin-1, or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of caveolin-1, an agonist or an antagonist or a competitive inhibitor of caveolin-1, a recombinant hsp90, a nucleic acid encoding the partial or total amino acid sequence of hsp90 or an analogue thereof or a pharmacologically acceptable derivative thereof, a compound modulating the expression of hsp90, an agonist or an antagonist or a competitive inhibitor of hsp90, a recombinant of Akt, a nucleic acid encoding the partial or total amino acid sequence of Akt, or an analogue thereof or a pharmacologically acceptable derivative thereof, a
Abstract: The invention is an apparatus and method for the treatment of prostate cancer, and involves administering an antibody that specifically binds with prostate antigen.
Type:
Application
Filed:
October 31, 2007
Publication date:
September 3, 2009
Applicant:
AltaRex Medical Corp.
Inventors:
Beatrice Leveugle, Ragupathy Madiyalakan, Antoine A. Noujaim, Birgit C. Schultes, Bruce Darryl Hirsche
Abstract: The present invention provides methods, compositions and vaccines for specifically targeting immunoglobulin associated cell-surface determinants that are not shed into the blood of a host. In some cases, the immunoglobulin associated cell-surface determinants will be involved in various B-cell disorders. The methods involve administering an IACSD targeting element to a B-cell. The method can employ treating an individual with a B-cell associated disorder by administering an effective amount of an IACSD targeting preparation. The compositions include isolated antibodies where the antibodies associate with an immunoglobulin associated cell-surface determinants. The invention also includes vaccines that immunize against immunoglobulin associated cell-surface determinants.
Abstract: The present invention discloses anti-idiotypic antibodies and fragments thereof against inhibitory Factor VIII anti-bodies, said inhibitory antibodies having an affinity for the C2 domain of Factor VIII. The anti-idiotypic antibodies of the present invention are able to completely neutralise in vitro and in an in vivo mouse model the inhibitory activity of FVIII inhibitors. The anti idiotypic antibodies of the present invention can be applied for the prevention, treatment or reduction of bleeding disorders of hemophilia patients with inhibitory antibody against the C2 domain of Factor VIII.
Type:
Grant
Filed:
July 28, 2003
Date of Patent:
September 1, 2009
Assignee:
D. Collen Research Foundation VZW
Inventors:
Jean Guy G. Gilles, Jean-Marie R. Saint-Remy, Marc G. Jacquemin
Abstract: A pharmaceutical composition for the treatment of cancer of which survival and/or metastasis is under the influence of signal transduction mediated by a chemokine receptor CXCR3, which comprises an agent to inhibit CXCR3, and a method of treatment and diagnosis of such cancer.
Abstract: The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.
Type:
Grant
Filed:
January 8, 2002
Date of Patent:
June 9, 2009
Assignee:
Baylor Research Institute
Inventors:
Jacques F. Banchereau, Anna Karolina Palucka, Patrick Blanco
Abstract: The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the Fc?RIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.
Type:
Application
Filed:
November 2, 2006
Publication date:
May 21, 2009
Applicant:
LFB BIOTECHNOLOGIES
Inventors:
Christian Behrens, Christine Gaucher, Christophe De Romeuf
Abstract: The present invention provides HEH4 polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing HEH4 polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with HEH4 polypeptides.
Abstract: The present invention refers to a pharmaceutical composition for parenteral administration as vaccine comprising a monoclonal antibody and as adjuvant an aluminium derivative.
Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and uses thereof.
Type:
Application
Filed:
December 8, 2006
Publication date:
April 2, 2009
Inventors:
Bjorn Frendeus, Roland Carlsson, Anne-Christine Carlsson
Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
Abstract: Antimineralocorticoid compounds are disclosed for use in the prophylaxis and therapy of viral infections, especially the retroviral infection by HIV. These compounds can be administered alone or in combination with conventional anti-viral agents or anti-sense mineralocorticoid Steroid ReceptorNA or DNA mutants of heat shock proteins.
Abstract: The invention relates to the use of a Dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof for the prevention, delay of progression or the treatment of neurodegenerative disorders, cognitive disorders and for improving memory (both short term and long term) and learning ability.
Abstract: The present invention relates generally to a method of treatment and/or prevention of hypersensitivity including anaphylaxis in patients receiving replacement therapy molecules that elicit an IgE-mediated response by administering an anti-IgE antibody or a binding fragment thereof. Anti-IgE antibodies inhibit IgE-mediated allergic reactions in the mammals and can also lower the risk of an anaphylactic reaction to a replacement therapy molecule. The administration of anti-IgE antibodies over time also downregulates the high-affinity IgE receptor, further decreasing the risk of hypersensitivity and/or anaphylaxis. The anti-IgE antibody binds to circulating or serum IgE and/or membrane form IgE on B-cells, but not to IgE bound to mast cells or basophils, as this may cause crosslinking. This method also reduces the dose and/or frequency of administration of the replacement therapy molecule by reducing or eliminating neutralizing IgE antibodies specific for the replacement therapy molecule.
Abstract: The present application relates to apoptotic anti-IgE antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use in the treatment of IgE-mediated disorders.
Type:
Application
Filed:
March 21, 2008
Publication date:
January 8, 2009
Applicant:
GENENTECH, INC.
Inventors:
Lawren Wu, Mercedesz Balazs, Hans Brightbill, Andrew Chan, Yvonne Chen, Anan Chuntharapai, Mark Dennis, Terence Wong
Abstract: The present invention refers to novel conjugate molecules and their use or the transport of nano- and macromolecular structures into cells and/or the nucleus. More particularly, the present invention refers to conjugate molecules containing a carrier, preferably thiopyridyl moieties, and a cargo moiety. Thereby, the thiopyridyl moiety is bound to the cargo moiety to act as a carrier, particularly for efficient intracellular and/or intranuclear delivery of drugs, nano-or macromolecular structures, etc. The novel conjugate molecules are provided for the manufacture of a medicament for gene therapy, apoptosis, or for the treatment of diseases such as cancer, autoimmune diseases or infectious diseases.
Abstract: An antibody or antibody fragment preparation being capable of specifically binding the amino acid sequence 60-76, 86-98, 135-149, 215-227, 363-377, 385-397, 405-419, 427-440, 509-522, 605-619, 635-649, 666-680, 696-711, 752-766, 836-851, 871-884, and/or 904-916 of NIK, or being capable of specifically binding a specific portion of the amino acid sequence is provided.
Type:
Application
Filed:
October 5, 2004
Publication date:
November 6, 2008
Applicant:
YEDA RESEARCH AND DEVELOPMENT CO., LTD
Inventors:
David Wallach, Parameswaran Ramakrishnan
Abstract: The present invention provides structures of small molecules capable of modulating apoptotic cell death. More specifically, the structures relate to the structures of apoptotic active sites of mammalian alpha-fetoprotein (AFP) and albumin. Peptides mimicking the active site contain two sequences, Arg-Gly-Asp and Asp-X-X-Asp, wherein X means any amino acid. These sequences are needed in the same molecule for causing a wide range of biological activities. The peptides can be utilized to suppress apoptotic pathways by inhibiting the cytochrome c-mediated caspase activation. Thus, the peptides can be used to inhibit effects of apoptosis induced by oxidative stress, drugs, cytokines, Fas-ligand, alpha-fetoprotein, used to prevent apoptosis in culturing cells, in organ transplantation, in immunological autoimmune disorders and immunodeficiency syndrome induced by viral infection, or to diminish side cytotoxic effects after chemotherapy and radiation therapy.
Type:
Grant
Filed:
October 7, 2003
Date of Patent:
November 4, 2008
Inventors:
Elena Ivanovna Dudich, Lidia Nikolaevna Semenkova, Igor Vyacheslavovitch Dudich, Edvward Borisovitch Tatulov, Dimitry Lvovicth Zubov, Timo Kalevi Korpela
Abstract: The use of ?-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method comprises administering a therapeutically effective amount of a ?-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol.
Abstract: Methods using internal image antibodies for photodiagnosis and/or phototherapy. The internal image antibodies are conjugated with a photoactive molecule such as a dye or photosensitizer, to target specific regions, such as biological receptors. The photoactive molecules are then activated for diagnosis or therapy. Advantageously, the internal image antibody is specific for a biological receptor, but does not require isolation of the receptor to prepare the antibody, and provides the desired specificity and selectivity for targeted diagnosis or therapy.
Type:
Grant
Filed:
January 21, 2004
Date of Patent:
October 7, 2008
Assignee:
Mallinckrodt, Inc.
Inventors:
Raghavan Rajagopalan, Joseph E. Bugaj, Samuel I. Achilefu, Richard B. Dorshow
Abstract: Methods of treatment of various non-demyelinating and demyelinating neural disorders are provided, comprising administering a serum composition obtained from a goat after challenge with an immunogen. Also provided are methods of treatment of certain autommune disorders using such a composition.
Abstract: The present invention provides a pharmaceutical composition comprising an Anti-IgE Antibody and at least one further immunosuppressive agent, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
Type:
Application
Filed:
February 2, 2006
Publication date:
August 28, 2008
Inventors:
Charles Edward Owen, Howard George Fox, Christoph Walker
Abstract: A humanized form of an anti-idiotype antibody to CEA, e.g., hWI2, has conserved immunoreactivity. The clinical benefits of anti-CEA antibodies are maximized by using the humanized anti-idiotype as a clearing agent for anti-CEA antibodies or antibody fragments. The humanized anti-idiotype also can be used as an immunogenic vaccine.
Type:
Grant
Filed:
July 25, 2007
Date of Patent:
August 19, 2008
Assignee:
Immunomedics, Inc.
Inventors:
Shui-on Leung, Michele J. Losman, Hans Hansen
Abstract: The present invention provides novel therapies and novel prophylactic methods for multiple sclerosis. Also provided are novel diagnostic methods. The invention resides in the finding that multiple sclerosis most likely is caused by chronic infection with a microorganism that cross-reacts immunologically with the spirochete Leptospira interrogans, which normally infects the brown rat.
Abstract: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.
Type:
Application
Filed:
November 15, 2007
Publication date:
August 7, 2008
Applicant:
Functional Genetics, Inc.
Inventors:
Limin Li, Michael Kinch, Michael Goldblatt
Abstract: Particular anti-LFL2 antibody compositions are provided herein. These antibodies may be used for diagnosis, prognosis, therapeutic monitoring and treatment of cancer, especially breast cancer, head/neck cancer, lung cancer, ovarian cancer, stomach cancer and pancreatic cancer. Furthermore, anti-LFL2 antibodies are provided herein which target the LFL2 stump remaining after proteolytic cleavage of the extracellular domain of LFL2. Additionally, anti-LFL2 antibodies are provided herein which target the stroma surrounding cancer tumors, wherein said stroma-targeting anti-LFL2 antibodies disrupt the integrity of the stroma surrounding the cancer tumor, and also make the stroma more permeable to chemotherapeutic agents and other molecular drug agents that target tumor cells.
Type:
Grant
Filed:
March 25, 2005
Date of Patent:
July 15, 2008
Assignee:
PDL BioPharma, Inc.
Inventors:
Yongke Zhang, Vanitha Ramakrishnan, Debbie Law
Abstract: The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A.
Type:
Application
Filed:
February 26, 2007
Publication date:
July 3, 2008
Inventors:
Jean-Guy Gilles, Marc G. Jacquemin, Jean-Marie Saint-Remy, Christian Behrens
Abstract: The present invention provides methods of delaying development of CEA-associated tumors using the anti-idiotype antibody 3H1, particularly in high-risk individuals.
Type:
Grant
Filed:
April 6, 2004
Date of Patent:
November 27, 2007
Assignee:
University of Kentucky Research Foundation
Inventors:
Malaya Chatterjee, Kenneth A. Foon, Sunil K. Chatterjee